Recently published studies on the development and use of recombinant v
accinia virus (VV) vaccines incorporating either the complete envelope
(env) gene or only a fragment of the env gene consisting of the codin
g sequence for the env glycoprotein 51 (gp51) and part of gp30 of the
bovine leukaemia virus (BLV) are described. It has been reported that
vaccination of sheep with recombinant VV vaccines containing the compl
ete env gene a pears to protect sheep against challenge infection with
BLV. The evidence for this protection is based on the lack of persist
ence of high titres of anti-gp51 antibodies compared with unvaccinated
BLV infected controls, on the enhanced CD4 proliferative responses to
specific BLV gp51 synthetic peptides in the vaccinated sheep, and on
the inability to detect BLV pro-virus by polymerase chain reaction in
the vaccinated sheep after 4 months following challenge infection comp
ared with continual detection in unvaccinated sheep over a 16 month tr
ial period. It has been suggested that cell-mediated immune responses
may be an important aspect of protective immunity against BLV infectio
n and it has been reported that large tracts of amino acid sequences w
ithin the env and pol genes are highly conserved in different isolates
from different countries which is of importance in designing peptide
derived vaccines.